文献速递前列腺癌

前列腺癌根治性调强放疗后长期泌尿生殖系统毒性:系统评价与Meta分析

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-03-08

该系统评价与Meta分析检索2008年1月至2021年12月的前瞻性研究,纳入6项研究,汇总60个月RTOG和CTCAE≥2级泌尿生殖系统毒性累积发生率分别为17%(95%CI:5-20%,n=678)和33%(95%CI:27-38%,n=153),血尿5%、尿失禁12%、尿潴留24%。作者结论认为报告60个月毒性的高质量研究少,保守估计的60个月毒性发生率较高,需要更长随访和一致的毒性报告标准。

要点

  • 纳入6项前瞻性研究,均采用常规分割,3项含大分割对照臂,均未涉及淋巴结照射。
  • 60个月RTOG≥2级泌尿生殖系统毒性累积发生率为17%(95%CI:5-20%,n=678)。
  • 60个月CTCAE≥2级泌尿生殖系统毒性累积发生率为33%(95%CI:27-38%,n=153)。

核心结论

  • 报告调强放疗后60个月毒性率的高质量研究较少,保守估计的60个月毒性率较高,需要更长随访和一致的毒性报告标准。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、EMBASE和Cochrane数据库2008年1月至2021年12月发表的前瞻性研究(PROSPERO方案CRD42019133320)。
  • 采用Cochrane偏倚风险2工具评估随机对照试验质量,采用纽卡斯尔-渥太华量表评估非随机对照试验质量。
  • 共筛选4721项研究,最终纳入6项符合标准的研究;所有研究均涉及常规分割,其中3项包含大分割对照臂,均未涉及淋巴结照射。

主要发现

  • 60个月RTOG≥2级泌尿生殖系统毒性累积发生率为17%(95%CI:5-20%,n=678)。
  • 60个月CTCAE≥2级泌尿生殖系统毒性累积发生率为33%(95%CI:27-38%,n=153)。
  • 60个月血尿累积发生率为5%(95%CI:-4-14%,n=48)。
  • 60个月尿失禁累积发生率为12%(95%CI:6-18%,n=194)。
  • 60个月尿潴留累积发生率为24%(95%CI:9-40%,n=10)。

关键数值与推荐

  • 1项研究报告了时间至事件分析,1项报告了预测因素,无研究报告经济分析或120个月毒性。
  • 研究间存在相当大的异质性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 报告60个月毒性率的高质量研究较少。
  • 研究间存在相当大的异质性。
  • 需要更长随访和一致的毒性报告标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies have shown that radiation-induced pelvic toxicity often requires urological consultation. However, the 10-year incidence of genitourinary toxicity following intensity-modulated radiotherapy (IMRT) amongst patients with localised prostate cancer remains unclear. Hence, we conducted a systematic review and meta-analysis to determine the incidence of late genitourinary toxicity relying on Radiation Therapy Oncology Group (RTOG) and Common Terminology Criteria for Adverse Events (CTCAE) grade as well as the incidence of specific genitourinary toxicity. Secondary objectives involved quantifing the number of studies reporting 120-month follow-up endpoints, time to event analysis, predictive factors or economic evaluation. METHODS: Articles published from January 2008 to December 2021 describing prospective studies were systematically searched in MEDLINE, EMBASE and Cochrane (PROSPERO protocol CRD42019133320). Quality assessment was performed by use of the Cochrane Risk of Bias 2 Tool for RCTs and the Newcastle Ottowa Scale for non-RCTs. Meta-analysis was performed on the 60-month incidence of RTOG and CTCAE Grade ≥2 genitourinary toxicity, haematuria, urinary retention and urinary incontinence. RESULTS: We screened 4721 studies and six studies met our inclusion criteria. All included studies involved normofractionation, three included a hypofractionation comparator arm and none involved nodal irradiation. The pooled 60-month cumulative incidence of RTOG and CTCAE Grade ≥2 genitourinary toxicity were 17% (95% CI: 5-20%, n = 678) and 33% (95% CI: 27-38%, n = 153), respectively. The pooled 60-month cumulative incidence of Haematuria was 5% (95% CI: -4-14%, n = 48), Urinary incontinence 12% (95% CI: 6-18%, n = 194), Urinary retention 24% (95% CI: 9-40%, n = 10). One study reported time to event analyses, one reported predictive factors, no studies reported economic analysis or 120-month toxicity. There was considerable heterogeneity amongst the studies. CONCLUSION: There are few high-quality studies reporting 60-month toxicity rates after IMRT. Conservative estimates of 60-month toxicity rates are high and there is need for longer follow-up and consistent toxicity reporting standards.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. David R, Buckby A, Kahokehr AA, et al. Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022. PMID: 35260794. doi:10.1038/s41391-022-00520-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。